CXCR4 and glioma: Although AMD3465 is another drug which is more specific than AMD3100 and has been shown to have anti-glioma effect in various models [48, 49], to rule out any unreported off target effects of both these drugs, we chose to selectively knock down CXCR4 expression using shRNA.